openPR Logo
Press release

Outlook of Viscosupplementation Market: Premium Analysis and Global Growth for 2016 - 2023

03-10-2017 02:04 PM CET | IT, New Media & Software

Press release from: TMR - Research Reports

Outlook of Viscosupplementation Market: Premium Analysis

Viscosupplementation is a minimally invasive procedure that involves injection of gel-like substances into a joint to assist the viscous properties of synovial fluid. As of now hyaluronate injections are only approved viscosupplementation treatment of osteoarthritis of the knee. Hyaluronic acid (HA) or hyaluronate is a non-sulfated glycosaminoglycan that is distributed throughout the body in epithelial, connective tissues, and neural tissues. Hyaluronic acid is observed to be an integral component of the extracellular matrix as it contributes significantly to migration and cell proliferation. Hyaluronic acid acts as a joint lubricant and elastic in nature that allows it to act as a shock absorber because of its viscous nature. Chemical modification allows Hyaluronic acid to transform into several physical forms such as soft or stiff hydrogels, non-woven meshes, flexible sheets, viscoelastic solutions, electrospun fibers, macroporous, fibrillar sponges, and nanoparticulate fluids for use in a range of preclinical and clinical applications. According to the WHO, osteoarthritis is a degenerative joint disease that mainly affects the articular cartilage and is related with aging. This condition affects the joints that have been continually stressed over the years including the hips, fingers, lower spine and knees. According to the WHO, globally, around 9.6% men and 18.0% women are above the age of 60 years and suffer from symptomatic osteoarthritis, which is one of the top disabling diseases in developed countries. Osteoarthritis is mostly classified in two types: primary and secondary where primary osteoarthritis occurs due to aging and wear and tear of joints and secondary osteoarthritis occurs due to an accident or obesity at an early stage.

Browse Market Research Report @ http://www.transparencymarketresearch.com/viscosupplementation-market.html

Factors driving the growth of viscosupplementation market are increasing geriatric population, increasing demand for minimally invasive surgical procedures, high patient awareness about new drugs and devices for the treatment of osteoarthritis and rising obese population globally. However, lack of safety and inefficiency of the products might hamper the market growth. The product innovation and process development is an opportunity window for market players as safety and efficacy are the major concerns of viscosupplementation products. Thus, introduction of products that helps to overcome these concerns have an opportunity to enter and establish in the global viscosupplementation market.

The FDA approved hyaluronates currently available in the viscosupplementation market are Hyalgan (Sanofi), Euflexxa (Ferring Pharmaceuticals, Inc.), Orthovisc (Anika Therapeutics), Supartz and Gel-One (Seikagaku Corporation), and Synvisc, Synvisc One (Genzyme) and Durolane (Q MED AB).

North America is the largest viscosupplementation market globally accounting for high product demand, high awareness in the region and acceptance of high priced products. Europe experienced an economic downturn that created problem in the hyaluronic acid products market as reimbursement policies turned out to be difficult but still the premium priced products were accepted in some of the countries. Although European market is expected to review and provide essential opportunity for viscosupplementation products as the economical conditions are reviving. Asia-Pacific and RoW observed to be the emerging markets for viscosupplementation and Asia-Pacific viscosupplementation market is especially driven by economic development, healthcare facility enhancements and high demand for minimally invasive surgeries.

Fill the form to gain deeper insights on this market @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=10232

Some of the key players of viscosupplementation market are Alcon, Inc., F. Hoffmann-La Roche Ltd., Allergan, Inc., Fidia Farmaceutici SpA, Anika Therapeutics, Inc., Ferring Pharmaceuticals, Inc., GALDERMA S.A., LifeCore Biomedical LLC, Hyaltech Ltd. and others.

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Outlook of Viscosupplementation Market: Premium Analysis and Global Growth for 2016 - 2023 here

News-ID: 464185 • Views: 252

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for Viscosupplementation

Global Viscosupplementation - Analysis and Market Forecasts
"The Report MediPoint: Viscosupplementation - Global Analysis and Market Forecasts provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" About Viscosupplementation Market Osteoarthritis (OA) constitutes a growing public health burden, and is the most common cause of musculoskeletal disability across the globe. Intra-articular viscosupplementation with hyaluronic acid (HA) has become an increasingly accepted therapeutic alternative to knee replacement surgery in the
Viscosupplementation Market - Global Industry Analysis 2025
Viscosupplementation is a treatment that helps reduce the joint pain and improves the functional condition of the osteoarthritic joint. It involves the injection of a thick fluid called hyaluronate into the knee. Hyaluronic acid is found in the viscous synovial fluid that lubricates the cartilage surfaces and protects the joints from shock. This acid is an elastic substance that is naturally secreted by mesothelial cells. Osteoarthritis—the most common type of
Viscosupplementation Market : Analysis and Forecast by 2023
Viscosupplementation is a minimally invasive procedure that involves injection of gel-like substances into a joint to assist the viscous properties of synovial fluid. As of now hyaluronate injections are only approved viscosupplementation treatment of osteoarthritis of the knee. Hyaluronic acid (HA) or hyaluronate is a non-sulfated glycosaminoglycan that is distributed throughout the body in epithelial, connective tissues, and neural tissues. Hyaluronic acid is observed to be an integral component of
Look Inside Viscosupplementation Market - Growth after 2017
Qyresearchreports include new market research report Global Viscosupplementation Sales Market Report 2017 to its huge collection of research reports. This report on the global Viscosupplementation market has been curated by research analysts of the industry, with a chief aim to put forth the current market conditions for the global Viscosupplementation. Its objective is to shed light on the prospects of growth of the market and reach out to a wide range
Viscosupplementation Market | Analysis & Key Trends 2023
Viscosupplementation is a minimally invasive procedure that involves injection of gel-like substances into a joint to assist the viscous properties of synovial fluid. As of now hyaluronate injections are only approved viscosupplementation treatment of osteoarthritis of the knee. Hyaluronic acid (HA) or hyaluronate is a non-sulfated glycosaminoglycan that is distributed throughout the body in epithelial, connective tissues, and neural tissues. Hyaluronic acid is observed to be an integral component of
Viscosupplementation Devices – Medical Devices Pipeline Assessment, 2017
ReportBazzar has released its latest research-based report entitled ‘Viscosupplementation’ market. This report provides a holistic approach to the market growth with a detailed and precise analysis of the overall competitive scenario of the Viscosupplementation market. The report also provides a detailed analysis of key trends and latest technologies, playing a prominent role in the Viscosupplementation market growth. It takes into account aspects such as drivers, restraints, challenges, and opportunities that impact